Home Diagnostics, Inc., a leading manufacturer and marketer of diabetes testing supplies, reached a settlement with Roche regarding a patent infringement suit filed in February 2004.

Roche had lodged a compliant against Home Diagnostics alleging that the latter's TrueTrack Smart System and TrackEASE Smart System blood glucose monitors infringed on US patent numbers 5,366,609 and Re. 36,268, relating to biosensing blood glucose monitors.

Among the terms of the settlement is a paid-up worldwide license under the patents at issue. The amount paid by Home Diagnostics will be recorded as an expense in its fourth quarter 2007 financial results. In addition, the settlement terms include a covenant by Roche not to sue Home Diagnostics on the licensed patents.

J. Richard Damron, Jr., president and chief executive officer of Home Diagnostics, said, "We are pleased to have reached a mutually beneficial settlement with Roche and will continue our strategy to bring affordable, high-performance blood glucose monitoring products to the diabetes market."

Based in Fort Lauderdale, Florida, Home Diagnostics is a leading developer, manufacturer and marketer of diabetes management solutions. Home Diagnostics offers a portfolio of high-quality blood glucose monitoring systems that spans the spectrum of features and benefits to help every person with diabetes better monitor and manage their disease.

Home Diagnostics' product line includes TrueTrack Smart System, Sidekick, TRUEread, TrackEASE Smart System and Prestige Smart System blood glucose monitoring systems.